BTAI

BioXcel Therapeutics Inc. Common Stock (BTAI)

Stock · NASDAQ · Health Care

$0.04785as of 10/8/2026

Price chart

Open in TradingView

Active signals

No technical signal is currently active for this symbol.

Support level
$0.037012
Industry
Biotechnology: Pharmaceutical Preparations

BTAI Signal Track Record

How signals performed across all stocks →

What BTAI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike40-13.5%35%
Bollinger Band Breakdown23-2.4%39%
Bollinger Band Breakout16-4.2%38%
200-Day Moving Average Touch4+29.7%75%
Any 20-session window (baseline)-10.8%34%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its n…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
29

Fundamentals

1-day range
$0.069$0.0935
Market cap
$25.63M
P/E (trailing)
—
P/E (forward)
-0.03
EPS (trailing)
$-3.78
Dividend yield
—
Beta
0.95
Avg. volume
11.06M
52-week range
$0.019$2.87
Next earnings: March 26, 2026 · EPS estimate $-0.68confirmed

How BioXcel Therapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$642.0KR&D$30.25M (4712%)SG&A$20.49M (3192%)Cost of Revenue$164.0K (26%)BTAI

Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub

Gross Profit$478.0K(74%)
Operating Income-$50.46M(-7860%)

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$38
+79314.8%
Median
$12
+24978.4%
Low
$5
+10349.3%

BioXcel Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • BTAI
    BioXcel Therapeutics Inc. Common Stock
    $0.04785
    ▼ 3.33%
    Market cap $25.63MP/E —
    $0.019$2.87
  • AYTU
    Aytu BioPharma Inc. Common Stock
    $2.04
    ▲ 1.49%
    Market cap $25.01MP/E —
    $1.8$3.07
  • ATNM
    Actinium Pharmaceuticals Inc. (Delaware) Common Stock
    $1.13
    ▲ 6.60%
    Market cap $24.69MP/E 2.95
    $0.7351$1.74
  • LGVN
    Longeveron Inc. Class A Common Stock
    $1.39
    ▼ 7.33%
    Market cap $24.44MP/E —
    $1.69$12.3
  • TXMD
    TherapeuticsMD Inc. Common Stock
    $1.9
    ▼ 1.55%
    Market cap $24.19MP/E 135.01
    $1.03$2.95
  • ABVC
    ABVC BioPharma Inc. Common Stock
    $0.918
    ▼ 1.61%
    Market cap $27.09MP/E —
    $0.7069$3.07
  • IGC
    IGC Pharma Inc. Common Stock
    $0.25
    ▲ 0.00%
    Market cap $23.94MP/E —
    $0.235$0.4508

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
164.3K
Disposed
39.7K

Institutional Ownership

March 31, 2026

Total shares held
5.35M
Total value held
$7.16M
Institutional holders
36
Top holders this quarter
  • Unknown1.94M
  • Unknown1.91M
  • Unknown241.2K
  • Unknown230.2K
  • Unknown207.3K
  • Unknown131.8K
  • Unknown96.5K
  • Unknown92.1K
  • Unknown90.3K
  • Unknown84.3K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.